Showing 2891-2900 of 20410 results for "".
DESTINY-Breast05 Findings Lead to New Indication for Trastuzumab Deruxtecan as Adjuvant Treatment for Residual Invasive Disease
https://reachmd.com/clinical-practice/oncology-hematology/destiny-breast05-findings-lead-to-new-indication-for-trastuzumab-deruxtecan-as-adjuvant-treatment-for-residual-invasive-disease/57225/Watch Dr. Hurvitz summarize the practice-changing data from DESTINY-Breast05 and why these findings led to updates in treatment guidelines for EBC.Individualized Management of Hyperkalemia: The Role of Potassium Binders in Patients With Cardiorenal Disease
https://reachmd.com/clinical-practice/nephrology/individualized-management-of-hyperkalemia-the-role-of-potassium-binders-in-patients-with-cardiorenal-disease/37619/Explore practical strategies and updated guidelines to better manage hyperkalemia, maintain RASi therapy, and select potassium binders in CKD and heart failure.Implementing Guideline-Concordant Care for a Patient With Newly Diagnosed BRAF-Mutant Stage IV Melanoma
https://reachmd.com/programs/cme/implementing-guideline-concordant-care-for-a-patient-with-newly-diagnosed-braf-mutant-stage-iv-melanoma/36328/Explore guideline-based treatment strategies and clinical data to optimize guideline-concordant care for patients with melanoma in the neoadjuvant, adjuvant, and metastatic settings.A Clear Horizon in Plaque Psoriasis: An Update on Investigational Oral Therapies
https://reachmd.com/programs/cme/a-clear-horizon-in-plaque-psoriasis-an-update-on-investigational-oral-therapies/37867/Join Drs. Armstrong and Stein Gold as they evaluate the clinical evidence and potential role of emerging oral systemic therapies in moderate to severe psoriasis.Clinical Data Prompting Guideline Updates for Subcutaneous ICIs in Melanoma
https://reachmd.com/programs/cme/clinical-data-prompting-guideline-updates-for-subcutaneous-icis-in-melanoma/36329/Explore guideline-based treatment strategies and clinical data to optimize guideline-concordant care for patients with melanoma in the neoadjuvant, adjuvant, and metastatic settings.Treating Primary Biliary Cholangitis with Seladelpar: Insights from the RESPONSE Trial
https://reachmd.com/programs/gi-insights/treating-primary-biliary-cholangitis-with-seladelpar-insights-from-the-response-trial/29162/Based on the RESPONSE trial, seladelpar may be a safe and effective treatment for primary biliary cholangitis patients who don’t response to current therapies.Healthy lifestyle interventions for CVD risk reduction in secondary prevention
https://reachmd.com/cme/obesity/healthy-lifestyle-interventions-for-cvd-risk-reduction-in-secondary-prevention/17755/3' education - Sep. 25, 2023 - Ruxandra Maria Christodorescu, MD and Nadia Bonekamp, MDRedefining First-Line Therapy of Metastatic TNBC: Integrating TROP2-Directed ADCs Into Modern Treatment Strategy
https://reachmd.com/programs/cme/redefining-first-line-therapy-of-metastatic-tnbc-integrating-trop2-directed-adcs-into-modern-treatment-strategy/56745/Explore how first-line TROP2-directed ADCs are reshaping metastatic TNBC care, with evidence-based treatment selection and proactive toxicity management.Inside the Decision: Case-Based Navigation of Brain Metastases in Breast and Lung Cancer
https://reachmd.com/programs/cme/inside-the-decision-case-based-navigation-of-brain-metastases-in-breast-and-lung-cancer/54766/Apply clinical evidence and multidisciplinary strategies to select and sequence systemic and local therapies for brain metastases in breast and lung cancer.Key Takeaways and Practice Integration
https://reachmd.com/programs/cme/Key-Takeaways-and-Practice-Integration/56710/Join Drs. Devries and Koetting evaluate screening methods for accurate diagnosis of Demodex blepharitis and optimal treatment strategies for this condition.